LLY Has Momentum. The Question Is The Price

A pharmaceutical giant is on an incredible run fueled by blockbuster drugs, forcing investors to ask if the price of admission already accounts for the entire victory lap.

Eli Lilly (LLY) makes medicines, and right now its treatments for diabetes and obesity are reshaping both the company and the market’s perception of it. The stock has climbed +53% in the last twelve months and trades just 5% below its two-year high. This is a genuine momentum stock, backed by a powerful business engine. The open question for any would-be buyer is this: the run is real, but is there anything left for a buyer at this price?

What’s actually powering this +53% run?

This is not a story stock. The run is fueled by exceptional business performance that dwarfs the typical large American company. Over the last twelve months, Lilly’s revenue grew 47%, crushing the S&P 500 median of 7.5%. Its operating margin is a remarkable 47%, more than double the market median of 18.4%.

The engine room for this performance is its cardiometabolic franchise. In the first quarter of 2026, its two key drugs in the space delivered a combined $12.8 billion in global revenue. This isn’t a one-time event; it’s the result of large demand for a new class of medicines, and Lilly is at the forefront of meeting it.

If the engine is so powerful, what’s the price of admission?

A ticket for this ride is not cheap. The market is well aware of the quality here and charges accordingly. Lilly trades at a price-to-earnings multiple of 41.6, a steep premium to the S&P 500 median of 24.3. Its price-to-sales multiple of 14.6 is more than the market median. The market is already pricing in a tremendous amount of success.

The honest catch for a buyer today extends beyond the valuation to the business reality that could stall the engine. That reality is pricing pressure. While volumes are exploding, management has been clear, stating they “still expect price to be a headwind in the low to mid-teens for the full year.” The long-term growth story depends on securing broad, stable insurance and employer coverage, a process that is far from guaranteed and presents a significant hurdle to maintaining the current pace.

Will the new billion revenue target hold up?

This brings the entire momentum question into sharp focus. Can the company’s huge volume growth continue to overwhelm the pricing friction? Management has signaled its confidence, raising its full-year revenue guidance by $2 billion. Hitting this new, higher range would be a clear signal that the business engine is still pulling harder than the pressures are blowing.

The ultimate test for investors sizing up this run is whether Lilly can deliver on that promise. The company’s ability to meet or beat its updated 2026 revenue guidance of $82 billion to $85 billion is the single most important watchable for the rest of the year.

If momentum backed by real numbers is your hunting ground, our Guidance Momentum screen tracks every S&P 500 name where a rising forecast is meeting real price strength.

And for anyone who would rather own the whole group than one company’s story, a healthcare ETF like XLV owns the whole group. That way no single company’s next surprise decides the outcome.

What Would You Do With A Gain Like LLY’s 417%?

Quality stocks in uptrends are exactly the positions that quietly take over portfolios. LLY is up 417% over the past five years, and gains like that are exactly how one holding quietly becomes too large a share of a portfolio. Whether that has happened in your portfolio is exactly what the Trefis Wealth team checks, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.